73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Pliant Therapeutics Inc
Closed
1.28 -2.29
Overview
Share price change
24h
Min
1.26
Max
1.31
Income | 17M -26M |
|---|---|
Employees | 171 |
EBITDA | 19M -23M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +132.56% upside |
Next Earnings | 26 Feb 2026 |
|---|
Market Cap | -21M 82M |
|---|---|
Previous open | 3.57 |
Previous close | 1.28 |
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Pliant Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Pliant Therapeutics Inc Forecast
Price Target
By TipRanks
132.56% upside
12 Months Forecast
Average 3 USD 132.56%
High 4 USD
Low 2 USD
Based on 4 Wall Street analysts offering 12 month price targets forPliant Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Live chat